MabVax Therapeutics Holdings Inc. (fka MBVXQ)

[bUrRpPPP!]

MBVX Chart perhaps we see a steady climb up now as the second 1/2 of 2016 nears... lots to look forward to as this one plays out imo.

Interim data from recently initiated pancreatic cancer trials is expected in mid-2016 (Q2/Q3) with final data readouts at the end of 2016. Data from their Sarcoma and Ovarian cancer vaccine programs, licensed from the renowned Memorial Sloan Kettering Cancer Center, are also expected to be released later in 2016. Furthermore, the company has initiated an option agreement in which Juno Therapeutics (JUNO) is utilizing their technology and patents to explore possible treatment indications. The agreement with Juno requires a response from Juno by June 30th, 2016 and if a partnership is formed it would likely contain license fees, milestone payments, and royalty-based compensation.